Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Inhibition of Jak-STAT3 pathway enhances bufalin-induced apoptosis in colon cancer SW620 cells

Authors: Zhitu Zhu, Enze Li, Yangyang Liu, Yu Gao, Hongzhi Sun, Guangyou Ma, Zhenghua Wang, Xiaomei Liu, Qingjun Wang, Xiujuan Qu, Yunpeng Liu, Yunlong Yu

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

The purpose of the research is to investigate the roles of Jak-STAT3 signaling pathway in bufalin-induced apoptosis in colon cancer SW620 cells.

Methods

The inhibitory effects of bufalin on cell proliferation were determined by MTT (Methyl thiazolyltetrazolium) assay. The morphological changes of cells were measured by Wright-Giemsa staining. The cell cycle arrest and apoptosis were tested by flow cytometry analysis. Western Blot was used to determine the protein expression of the apoptosis inhibitors livin and caspase-3, the apoptosis-related proteins Bax and Bcl-2, as well as the key protein kinases in the Jak-stat3 signaling pathway, stat3 and p-stat3.

Results

(1) Bufalin inhibited the proliferation of SW620 cells. IC50 at 24 h, 48 h and 72 h were 76.72 ± 6.21 nmol/L, 34.05 ± 4.21 nmol/L and 16.7 ± 6.37 nmol/L. (2) Bufalin induced SW620 cell cycle arrest and apoptosis, indicated by the appearance of apoptotic bodies; (3) The results from flow cytometry demonstrated that there was cell cycle G2/M phase arrest in 20 nmol/L bufalin treatment group (36.29 ± 2.11% vs 18.39 ± 1.74%, P<0.01); there was a sub-diploid apoptosis peak in 80 nmol/L bufalin treatment group (19.69 ± 1.63% vs 0.99 ± 0.23%, P <0.01). The apoptosis rate was 34.63 ± 2.57% (vs 19.69 ± 1.63%, P = 0.002) in JAK kinase inhibitor AG490 plus bufalin treatment group. (4) During the process of bufalin-induced apoptosis in SW620 cells, transient activation of p-stat3 inhibited the activation of stat3, up-regulated Bax expression, down-regulated livin and Bcl-2 expression (P<0.01), and activated caspase-3. Inhibition of Jak-stat3 signaling pathway by pre-treatment with AG490 significantly enhanced the bufalin-induced apoptosis (P<0.01), further up-regulated Bax protein expression, down-regulated livin and Bcl-2 protein expression and enhanced caspase-3 activation.

Conclusions

Bufalin not only inhibited the growth of colon cancer SW620 cells, but also induced apoptosis of SW620 cells. Activation of caspase-3, up-regulation of Bax, down-regulation of livin and Bcl-2, as well as inhibition of Jak-stat3 signaling pathway might be the important mechanisms for the bufalin-induced apoptosis.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.CrossRefPubMed
2.
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010, 28: 4706-4713. 10.1200/JCO.2009.27.6055.CrossRefPubMed
3.
Krenn L, Kopp B: Bufadienolides from animal and plant sources. Phytochemistry. 1998, 48: 1-29. 10.1016/S0031-9422(97)00426-3.CrossRefPubMed
4.
Cao-Hong , Shibayama-Imazu T, Masuda Y, Shinki T, Nakajo S, Nakaya K: Involvement of Tiam1 in apoptosis induced by bufalin in HeLa cells. Anticancer Res. 2007, 27: 245-249.PubMed
5.
Tian X, Wang PP, Liu YP, Hou KZ, Jin B, Luo Y, Qu XJ: Effect of bufalin-inducing apoptosis on Bcl-2 and PKC in HL-60 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007, 15: 67-71.PubMed
6.
Liu Y, Qu X, Wang P, Tian X, Luo Y, Liu S, Lu X: WT1 downregulation during K562 cell differentiation and apoptosis induced by bufalin. Zhonghua Xue Ye Xue Za Zhi. 2002, 23: 356-359.PubMed
7.
Tian X, Luo Y, Liu YP, Hou KZ, Jin B, Zhang JD, Wang S: Downregulation of Bcl-2 and survivin expression and release of Smac/DIABLO involved in bufalin-induced HL-60 cell apoptosis. Zhonghua Xue Ye Xue Za Zhi. 2006, 27: 21-24.PubMed
8.
Watabe M, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K: The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J Biol Chem. 1996, 271: 14067-14072. 10.1074/jbc.271.24.14067.CrossRefPubMed
9.
Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship. Ann NY Acad Sci. 2009, 1171: 59-76. 10.1111/j.1749-6632.2009.04911.x.PubMedCentralCrossRefPubMed
10.
Huang S: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res. 2007, 13: 1362-1366. 10.1158/1078-0432.CCR-06-2313.CrossRefPubMed
11.
Scheper MA, Nikitakis NG, Sauk JJ: Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer. Int J Oral Maxillofac Surg. 2007, 36: 632-639. 10.1016/j.ijom.2007.04.003.CrossRefPubMed
12.
Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, Sekikawa A, Kawada M, Suzuki K, Kayahara T, Fukui H, Sawada M, Chiba T: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004, 23: 4921-4929. 10.1038/sj.onc.1207606.CrossRefPubMed
13.
Haura EB, Turkson J, Jove R: Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2005, 2: 315-324.CrossRefPubMed
14.
Kawazoe N, Watabe M, Masuda Y, Nakajo S, Nakaya K: Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene. 1999, 18: 2413-2421. 10.1038/sj.onc.1202555.CrossRefPubMed
15.
Chen A, Yu J, Zhang L, Sun Y, Zhang Y, Guo H, Zhou Y, Mitchelson K, Cheng J: Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. BiotechnolLett. 2009, 31: 487-494.
16.
Takai N, Ueda T, Nishida M, Nasu K, Narahara H: Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008, 21: 637-643.PubMed
17.
Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng Y, Zhang J, Liu Y: PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs. 2009, 20: 59-64. 10.1097/CAD.0b013e3283160fd6.CrossRefPubMed
18.
Xie CM, Chan WY, Yu S, Zhao J, Cheng CH: Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med. 2011, 51: 1365-1375. 10.1016/j.freeradbiomed.2011.06.016.CrossRefPubMed
19.
Jing Y, Watabe M, Hashimoto S, Nakajo S, Nakaya K: Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res. 1994, 14: 1193-2008.PubMed
20.
Watabe M, Ito K, Masuda Y, Nakajo S, Nakaya K: Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene. 1998, 16: 779-787. 10.1038/sj.onc.1201592.CrossRefPubMed
21.
Sun Y, Lin Y, Li H, Liu J, Sheng X, Zhang W: 2,5-Hexanedione induces human ovarian granulosa cell apoptosis through BCL-2, BAX, and CASPASE-3 signaling pathways. Arch Toxicol. 2012, 86: 205-215. 10.1007/s00204-011-0745-7.CrossRefPubMed
22.
Yan B: Research progress on Livin protein: an inhibitor of apoptosis. Mol Cell Biochem. 2011, 357: 39-45. 10.1007/s11010-011-0873-7.CrossRefPubMed
23.
Kitamura H, Honma I, Torigoe T, Hariu H, Asanuma H, Hirohashi Y, Sato E, Sato N, Tsukamoto T: Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients. Urology. 2007, 70: 38-42.CrossRefPubMed
24.
Chang H, Schimmer AD: Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther. 2007, 6: 24-30. 10.1158/1535-7163.MCT-06-0443.CrossRefPubMed
25.
Wang Q, Huang Y, Ni Y, Wang H, Hou Y: siRNA targeting midkine inhibits gastric cancer cells growth and induces apoptosis involved caspase-3,8,9 activation and mitochondrial depolarization. J Biomed Sci. 2007, 14: 783-795. 10.1007/s11373-007-9192-0.CrossRefPubMed
26.
Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, Bromberg J: Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 2006, 66: 9714-9721. 10.1158/0008-5472.CAN-05-4280.CrossRefPubMed
27.
Yao X, Zhu F, Zhao Z, Liu C, Luo L, Yin Z: Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway. J Cell Biochem. 2011, 112: 2837-2849. 10.1002/jcb.23198.CrossRefPubMed
28.
Wang Z, Jin H, Xu R, Mei Q, Fan D: Triptolidedownregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med. 2009, 41: 717-727. 10.3858/emm.2009.41.10.078.PubMedCentralCrossRefPubMed
29.
Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T, Sekine I: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep. 2006, 15: 1445-1451.PubMed
30.
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J: STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells. Cancer Res. 2011, 71: 7226-7237. 10.1158/0008-5472.CAN-10-4660.PubMedCentralCrossRefPubMed
31.
Xi RC, Biao WS, Gang ZZ: Significant elevation of survivin and livin expression in human colorectal cancer: inverse correlation between expression and overall survival. Onkologie. 2011, 34: 428-432. 10.1159/000331132.CrossRefPubMed
Metadata
Title
Inhibition of Jak-STAT3 pathway enhances bufalin-induced apoptosis in colon cancer SW620 cells
Authors
Zhitu Zhu
Enze Li
Yangyang Liu
Yu Gao
Hongzhi Sun
Guangyou Ma
Zhenghua Wang
Xiaomei Liu
Qingjun Wang
Xiujuan Qu
Yunpeng Liu
Yunlong Yu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-228

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue

Research

Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study

Review

Surgical treatment of liver metastases of gastric cancer: state of the art

Research

Two-year quality of life after free flap reconstruction in tumor-site discrepancy among Taiwanese with moderately advanced oral squamous cell carcinoma

Research

Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancer

Research

Clinical significance of clusterin expression in pancreatic adenocarcinoma

Case report

Leiomyosarcoma of the inferior vena cava level II involvement: curative resection and reconstruction of renal veins